what can we possibly learn from a "top-line" study or just three months of data?
again even if their is good news what is the cost of bringing this candidate drug to production? based on the current "pizza oven" costs of arikase phase 3 trials burning through insmed cash a mammoth secondary would be in order. so good news is now bad news for surviving shareholders. i am sorry.
I don't understand why you keep talking about "just three months". They are releasing top line results of the study is that something new to you? Sounds to me like your running out of things to bash on so your reaching for anything at this point. I'm sorry you got stuck short.